Shanghai-based 111 In., which runs an online retail drugstore and healthcare platform in China, has filed for U.S. initial public offering to raise US$200 million under the name YI, according to its prospectus.
Suzhou-based bio-pharmaceutical company TOT Biopharm has raised US$102 million series B round led by Chinese local asset management 99Fund, according to the company’s announcement.
Suzhou city, Jiangsu Province-based biotech firm CureGenetics Co., Ltd has raised a US$17 million series A round led by Qiming Venture Partners.
To tackle China’s structural shortage of quality healthcare services, technology and innovation can play an important role beside regulatory reform, Jiang Xiaodong, managing partner of Chinese venture firm Long Hill Capital, told China Money Network.
Chinese investment firm Decheng Capital has led a US$30 million series C round in Nanjing-based pharmaceutical firm Impact Therapeutics.
Hillhouse Capital and Chinese healthcare-focused investment firm Decheng Capital have led a US$60 million series B found in San Diego-based DNA sequencing platform developer Omniome, Inc.
Chinese private equity firm Legend Capital has joined China Renaissance’s healthcare fund to co-lead an investment worth nearly RMB2 billion (US$293 million) in Chinese Diagnostics Medical Corporation.
Chinese medical solution provider Medlinker has raised a RMB1 billion (US$146.8 million) series D round led by China Capital Zhongcai Fund, an industrial fund management company jointly sponsored by China Investment Securities, Zhongcai Financial Holding Investment LTD and others.
Chinese consumer medical beauty platform Igengmei raised a US$50 million series D1 round from Xiamen-based technology company Meitu and Shenzhen-based FOFs DH Fund.
Hillhouse Capital has led a US$230 million series B preferred stock financing in San Diego-based biopharmaceutical firm Gossamer Bio, according to the latter’s announcement.
China Capital Investment Group (CCIG), a subsidiary of CICC, has led a RMB700 million (US$102.67 million) series B round in Beijing Allcure Medical Technology Co. Ltd., which develops standardized tumor diagnosis and treatment centers.
Ascentage Pharma, a Chinese clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancer and other diseases, announced that it has raised a US$150 million series C round co-led by YuanMing Prudence Fund and Oriza Seed Venture Capital, as well as new investor Teng Yue Partners.
Chinese artificial intelligence company iFlytek has led a US$3.8 million Pre-A round in Cyrcadia Asia, that develops a smart wearable bra insert and provides accurate early breast cancer detection.
One of the largest Chinese investment banks in offshore markets, Hong Kong-based Haitong International Securities Group led a Series B financing round in Boston-based biotech research firm Orig3n, according to the latter’s statement.
iCarbonX , a Chinese artificial intelligence-enabled health data mining start-up, has signed a strategic cooperation agreement with COFCO NHRI, the central research institute under Beijing-based agricultural conglomerate COFCO Corporation, to push for the dynamic blood sugar research and its related application development.
Hangzhou-based biopharmaceutical company Adlai Nortye Biopharma announced that it has raised a US$53 million series B round from Matrix Partners China and other investors.
A consortium led by Jack Ma-backed Yunfeng Capital and Shenzhen-listed Chinese biopharmaceutical company Hybio Pharmaceutical has entered into an agreement to buy all the shares of German speciality pharmaceutical firm AMW GmbH, according to the latter’s announcement.
China Investment Corporation (CIC), a sovereign wealth fund has participated in a RMB1 billion (US$151 million) series D round in Beijing-based oncology, big data firm LinkDoc Technology Ltd.
Shenzhen government-backed venture capital firm Shenzhen Capital Group Co., Ltd., has led a series B round worth of hundreds of millions of RMB in Shenzhen-based genetic sequencing company HaploX, according to Haplox’s announcement.
Nuance Biotech, a China-based specialty pharmaceutical company, today announced series B fundraising of US$20 million with additional capital US$15 million tied to its acquisition of new products, led by C-Bridge Capital, a private equity firm focused on Chinese healthcare market.
China Merchants Capital has invested in a series A round worth hundreds of millions of RMB in Chinese third-party chemotherapy service franchise Beijing 5 Color Technology, according to the latter’s announcement.
SenseTime, a Chinese artificial intelligence unicorn worth US$4.5 billion, has led a US$75 million series B round in Chinese hospital wifi provider Helian Health.
Chinese biotech firm Alpha Biopharma Inc. announced that it has completed US$37 million of its US$65 million series A financing round led by Qiming Venture Partners.
A unit of Chinese investment firm CITIC Capital Holdings Ltd. has offered to buy NASDAQ-listed biotech firm China Biologic Products Holdings, Inc. for US$3.65 billion, according to a security filing by CITIC. The unit, CCRE, offered US$110 in cash for each share for the company. With 33.2 million shares outstanding, the transaction is worth around US$3.65 billion. With the Hong Kong Stock Exchange and Chinese domestic regulators implementing drastic changes to IPO policies to attract the so-called "new economy" companies …
Australian medical device company Sirtex Medical Limited (ASX: SRX) announced today that its board of directors has recommended acceptance of a A$1.87 billion (US$1.4 billion) acquisition proposal by Chinese alternative asset fund manager CDH Investments.
Yaoshibang, a Guangzhou-based online pharmacy trading and education platform, announced that it has completed a RMB420 million (US$65.7 million) series C round led by Shunwei Capital and DCM Ventures.
Shanghai-based pharmaceutical and medical device firm WuXi AppTec has led a strategic funding round in Insilico Medicine, a Baltimore-based artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research.
WuXi Biologics (2269.HK), an open-access biologics technology company based in China, is to invest US$60 million and hire approximately 150 employees to establish a biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility, the firm said today in an announcement.
Beijing and Hong Kong-based investment firm Hillhouse Capital has led a US$35 million series B+ round in antibody and recombinant protein biotherapeutics firm Hangzhou Just Biotherapeutics (HJB).
China’s Zhejiang Silk Road Fund has participated in a US$100 million series B round in CMR Surgical Ltd, a British company developing surgical robots.
Chinese alternative asset fund manager CDH Investments and Beijing-based Leadyond Capital have led a RMB250 million (US$39 million) series B round in Chengdu-based drug discovery firm HitGen, according to HitGen’s announcement.